Keros Therapeutics to Hold Corporate Update Call and Webcast

LEXINGTON, Mass., June 04, 2024 – Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of innovative treatments for conditions related to abnormal signaling of the transforming growth factor-beta (TGF-ß) family, has scheduled a corporate update conference call and webcast on June 17, 2024, at 8:00 a.m. Eastern time.

Dr. Jasbir S. Seehra, President and CEO of Keros, announced that the U.S. Food and Drug Administration (FDA) has provided favorable feedback on KER-050 (elritercept) for myelodysplastic syndromes (MDS). This feedback aligns with the design and endpoints proposed for the pivotal Phase 3 clinical trial involving MDS patients. Additionally, Dr. Seehra expressed anticipation regarding the progress of Keros’ pipeline, including the ongoing Phase 2 TROPOS trial for KER-012 (cibotercept) aimed at treating pulmonary arterial hypertension (PAH). The company expects to complete enrollment for this trial in the fourth quarter of 2024.

The live webcast of the conference call can be accessed on the Keros website. Domestic participants can join by dialing (877) 407-0309, while international participants can dial (201) 389-0853. A recorded version of the call will be available on the Keros website's Investors section for 90 days after the call.

Keros Therapeutics, Inc. is committed to developing and commercializing groundbreaking therapeutics for a wide array of conditions related to defective TGF-ß signaling. The company leads the field in understanding the TGF-ß family of proteins, which are crucial for the growth, repair, and maintenance of tissues such as blood, bone, skeletal muscle, adipose, and heart tissue. Through this knowledge, Keros has developed protein therapeutics with the potential for significant therapeutic benefits.

Keros’ leading product, KER-050 (elritercept), is intended to treat low blood cell counts, including anemia and thrombocytopenia, in MDS and myelofibrosis patients. The second product, KER-012 (cibotercept), targets the treatment of PAH and cardiovascular disorders. The third product, KER-065, focuses on treating obesity and neuromuscular diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!